Clinical trials: Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver
Vitamin D Replacement in Nonalcoholic Fatty Liver Disease
Vitamin D deficiency is very common in patients with fatty liver disease as evidenced by our observations in the Metabolic Liver Clinic and that reported by others.
- Trial name
- NCT03084328
- Testing
- Vitamind D
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- The Cleveland Clinic
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NASH With Fibrosis
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and metabolite identification of 14C- labelled rencofilstat ([14C] CRV431).
- Trial name
- NCT05737433
- Testing
- [14C]-rencofilstat 225mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
MAFLD
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
This real-world clinical trial evaluates the effectiveness of semaglutide (target dose is 2.4 mg/week) over 154 weeks (3 years) prescribed to the patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and…
- Trial name
- NCT06983171
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Center of target therapy
Non Alcoholic Steatohepatitis
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- FLIRT (NCT00492700)
- Testing
- rosiglitazone
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Association pour la Recherche sur les Maladies Hépatiques Virales
Metabolic Dysfunction-Associated Fatty Liver Disease
CPET-based HIIT for MAFLD
High-intensity interval training (HIIT), as an individualized exercise training mode based on cardiopulmonary exercise testing (CPET), is characterized by high-intensity training sessions interspersed with short rest periods.
- Trial name
- CEPHIT (NCT07177963)
- Testing
- HIIT, No specific exercise intervention.
- Where
- 5 sites in China
- Volunteers
- 54 people
- Sponsor
- Tang Yida
Non-Alcoholic Steatohepatitis (NASH)
A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled first-in-human study in which the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects
- Trial name
- NCT04481594
- Testing
- HPN-01
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hepanova Inc.
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
- Trial name
- NCT03976401
- Testing
- EFX
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 110 people
- Sponsor
- Akero Therapeutics, Inc
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects.
- Trial name
- NCT06308874
- Testing
- Amg dose administration group, Bmg dose administration group
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
NASH - Nonalcoholic Steatohepatitis
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
- Trial name
- NCT04054310
- Testing
- Liver Multi Scan
- Where
- 7 sites in United States
- Volunteers
- 225 people
- Sponsor
- Perspectum
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease
Assess the renal changes in patients with non-alcoholic fatty liver (NAFLD).
- Trial name
- NCT03487068
- Testing
- The FibroScan device
- Volunteers
- 50 people
- Sponsor
- Assiut University
Surgery, Obesity
A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² > BMI ≥ 30 kg/m²) with…
- Conditions
- Surgery, Obesity, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NASHSURG (NCT03472157)
- Testing
- Lifestyle therapy, Bariatric surgery
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Fatty Liver, Nonalcoholic
The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver
L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is involved in transporting fatty acids across the mitochondrial membrane, it could be an important component in treating a fatty liver disease.
- Trial name
- NCT03319199
- Testing
- "SLIM WATER"
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Rawi Hazzan
Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
- Trial name
- NCT05053165
- Testing
- LB-P6, LB-P8
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- LISCure Biosciences
Obesity, Morbid, Bariatric Surgery Candidate
Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery
Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases benefit from weight loss e.g. after bariatric surgery.
- Conditions
- Obesity, Morbid, Bariatric Surgery Candidate, NAFLD, Microbiome
- Trial name
- NCT03391401
- Testing
- Bariatric surgery
- Where
- 2 sites in Germany
- Volunteers
- 204 people
- Sponsor
- St. Franziskus Hospital
NAFLD, Diabetes Mellitus, Type 2
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes
The overall aim of this study is to investigate the long-term impact of a customized diet aimed at reducing liver fat specifically and a healthy Nordic diet on ectopic fat (liver, pancreatic and visceral) and cardiometabolic risk…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, PreDiabetes
- Trial name
- NAFLDiet (NCT04527965)
- Testing
- Customized diet to reduce liver fat, Healthy Nordic diet, Control
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Non-alcoholic Fatty Liver Disease (NAFLD)
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been steadily increasing, with 10-20% of affected individuals progressing to non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT06913699
- Testing
- Ultrasonund-guided percutaneous liver biopsy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai East Hospital
Non-alcoholic Steatohepatitis, Hepatic Impairment
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with…
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Trial name
- NCT05835180
- Testing
- TVB-2640 - 50 mg
- Where
- 3 sites in United States, Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.